Canadian and U.S. Banks Exit Climate Alliance Amid Policy Shifts 
The Silicon Valley venture capitalists who want to ‘move fast and break things’ in the defence industry 
BlackRock Settles ESG Disclosure Dispute with Tennessee Attorney General 
Say it with a picture: overcoming legalese in public procurement contracts 
S&P 500 Surges Ahead of Trump Inauguration as Markets Rally 
TikTok Ban Sparks Panic Among Advertisers as Deadline Looms 
Cleveland Fed President Warns of Ongoing Inflation Challenge 
Nintendo Unveils Switch 2 Console, Launch Expected This Year 
Starbucks CEO Announces Job Cuts to Streamline Operations 
GOP States File Lawsuit Against Biden's Offshore Drilling Restrictions 
How the UK’s plans for AI could derail net zero – the numbers explained 
Meta’s shift to ‘community notes’ risks hurting online health info providers more than ever 
TikTok Set to Shut Down in the U.S. Sunday Without Biden's Clarity 
TSMC Faces Challenges in Bringing Advanced Chipmaking to U.S. 
EV Startup Canoo Files for Chapter 7 Bankruptcy 
The LA fires have prompted a reckoning for the insurance industry – Australian premiums could soar as a result 
China's Refining Industry Faces Major Shakeup Amid Challenges 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
